菲律宾轮状病毒疫苗接种的成本效益:一项建模研究
INTRODUCTION: Rotavirus gastroenteritis (RVGE) remains a leading cause of hospitalization and death in children under five years of age in the Philippines.…
要点
- 接种任一种轮状病毒疫苗可在2021—2031年减少约40%的轮状病毒胃肠炎就诊、住院和死亡。
- Rotavac在支付意愿阈值为人均GDP 0.5倍时具有成本效益的概率超过99%。
核心结论
- Rotavac和Rotasiil在菲律宾可能具有成本效益,但无法明确应优先选择哪一种产品。
- Rotarix和Rotateq预期以更高成本提供相似获益,需定价更具竞争力才可考虑引入。
研究设计与样本
- 采用比例结局模型,从政府和社会视角计算2021—2031年10年间四种轮状病毒疫苗(Rotavac、Rotasiil、Rotarix、Rotateq)接种与否的疾病事件、DALY、接种项目成本和医疗成本。
- 主要结局指标为每避免1个DALY的成本,假设各产品产生相似获益,识别成本最低的优势产品,并与人均GDP 0.5倍和1倍(3485美元)的支付意愿阈值比较,进行确定性和概率敏感性分析。
主要发现
- 接种任一种轮状病毒疫苗可在2021—2031年避免约40%的轮状病毒胃肠炎就诊、住院和死亡。
- 其他产品提供相似获益但成本更高。
- 在支付意愿阈值为人均GDP 0.5倍时,Rotavac具有成本效益的概率超过99%。
关键数值与推荐
- 支付意愿阈值设定为人均GDP的0.5倍和1倍,人均GDP为3485美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rotavirus gastroenteritis (RVGE) remains a leading cause of hospitalization and death in children under five years of age in the Philippines. Rotavirus (RV) vaccination was introduced into the national immunization program (NIP) in 2012 but has since been limited to one region due to cost considerations and conflicting local cost-effectiveness estimates. Updated estimates of the cost-effectiveness of RV vaccination are required to inform prioritization of national immunization activities. METHODS: We calculated the potential costs and benefits of rotavirus vaccination over a 10-year-period (2021-2031) from a government and societal perspective, comparing four alternative rotavirus vaccines: Rotavac, Rotasiil, Rotarix and Rotateq. For each vaccine, a proportionate outcomes model was used to calculate the expected number of disease events, DALYs, vaccination program costs, and healthcare costs, with and without vaccination. The primary outcome measure was the cost per DALY averted. Assuming each product would generate similar benefits, the dominant (lowest cost) product was identified. We then calculated the cost-effectiveness (US$ per Disability Adjusted Life Year [DALY] averted) of the least costly product and compared it to willingness-to-pay thresholds of 0.5 and 1 times the national GDP per capita ($3,485), and ran deterministic and probabilistic sensitivity analyses. RESULTS: Introducing any of the four rotavirus vaccines would avert around 40% of RVGE visits, hospitalizations, and deaths over the period 2021-2031. Over the same ten-year period, the incremental cost of vaccination from a government perspective was estimated to be around $104, $105, $220, and $277 million for Rotavac, Rotasiil, Rotarix and Rotateq, respectively. The equivalent cost from a societal perspective was $58, $60, $178 and $231 million. The cost-effectiveness of the least costly product (Rotavac) was $1,148 ($830-$1682) from a government perspective and $646 ($233-1277) from a societal perspective. All other products offered similar benefits but at a higher cost. There is a >99% probability that Rotavac would be cost-effective at a willingness-to-pay threshold set at 0.5 times the national GDP per capita. CONCLUSION: Both Rotavac and Rotasiil are likely to be cost-effective options in the Philippines, but it is not possible to say definitively which product should be preferred. Rotarix and Rotateq are expected to offer similar benefits at more cost, so would need to be priced far more competitively to be considered for introduction.
引用
- Villanueva-Uy MET, Lam HY, Aldaba JG, et al. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study. Vaccine. 2021. PMID: 34753614. doi:10.1016/j.vaccine.2021.09.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。